CN114869982A - Traditional Chinese medicine composition for treating constipation and application thereof - Google Patents
Traditional Chinese medicine composition for treating constipation and application thereof Download PDFInfo
- Publication number
- CN114869982A CN114869982A CN202210729676.9A CN202210729676A CN114869982A CN 114869982 A CN114869982 A CN 114869982A CN 202210729676 A CN202210729676 A CN 202210729676A CN 114869982 A CN114869982 A CN 114869982A
- Authority
- CN
- China
- Prior art keywords
- parts
- weight
- traditional chinese
- chinese medicine
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 72
- 239000000203 mixture Substances 0.000 title claims abstract description 60
- 206010010774 Constipation Diseases 0.000 title claims abstract description 47
- 208000031971 Yin Deficiency Diseases 0.000 claims abstract description 11
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 10
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 10
- 241001522129 Pinellia Species 0.000 claims abstract description 9
- 235000006886 Zingiber officinale Nutrition 0.000 claims abstract description 9
- 235000008397 ginger Nutrition 0.000 claims abstract description 9
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 9
- 235000011477 liquorice Nutrition 0.000 claims abstract description 9
- 208000011580 syndromic disease Diseases 0.000 claims abstract description 9
- 244000274050 Platycodon grandiflorum Species 0.000 claims abstract description 7
- 235000006753 Platycodon grandiflorum Nutrition 0.000 claims abstract description 7
- 230000004069 differentiation Effects 0.000 claims abstract description 5
- 244000273928 Zingiber officinale Species 0.000 claims abstract 3
- 239000002994 raw material Substances 0.000 claims description 15
- 238000002360 preparation method Methods 0.000 claims description 11
- 239000002552 dosage form Substances 0.000 claims description 9
- 239000006187 pill Substances 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 6
- 239000003826 tablet Substances 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 4
- 238000005303 weighing Methods 0.000 claims description 3
- 241001522232 Pinellia ternata Species 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 30
- 230000000694 effects Effects 0.000 abstract description 16
- 239000007788 liquid Substances 0.000 abstract description 3
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 3
- 238000012360 testing method Methods 0.000 abstract description 2
- 230000002040 relaxant effect Effects 0.000 abstract 1
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 16
- 229940079593 drug Drugs 0.000 description 10
- 230000007812 deficiency Effects 0.000 description 9
- 239000012530 fluid Substances 0.000 description 9
- 210000002429 large intestine Anatomy 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 7
- LVRVABPNVHYXRT-BQWXUCBYSA-N 52906-92-0 Chemical compound C([C@H](N)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O)C(C)C)C1=CC=CC=C1 LVRVABPNVHYXRT-BQWXUCBYSA-N 0.000 description 7
- 102400000921 Gastrin Human genes 0.000 description 7
- 108010052343 Gastrins Proteins 0.000 description 7
- 102400001357 Motilin Human genes 0.000 description 7
- 101800002372 Motilin Proteins 0.000 description 7
- 102400000096 Substance P Human genes 0.000 description 7
- 101800003906 Substance P Proteins 0.000 description 7
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 206010067484 Adverse reaction Diseases 0.000 description 6
- 241000234314 Zingiber Species 0.000 description 6
- 230000006838 adverse reaction Effects 0.000 description 6
- 210000001835 viscera Anatomy 0.000 description 6
- 230000004064 dysfunction Effects 0.000 description 5
- 235000012907 honey Nutrition 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 241001127714 Amomum Species 0.000 description 4
- 235000002226 Ranunculus ficaria Nutrition 0.000 description 4
- 241001530126 Scrophularia Species 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 235000013399 edible fruits Nutrition 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 244000183685 Citrus aurantium Species 0.000 description 3
- 235000007716 Citrus aurantium Nutrition 0.000 description 3
- 241001673966 Magnolia officinalis Species 0.000 description 3
- 240000002948 Ophiopogon intermedius Species 0.000 description 3
- 235000006751 Platycodon Nutrition 0.000 description 3
- 240000003582 Platycodon grandiflorus Species 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000013872 defecation Effects 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000003908 liver function Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 229930189914 platycodon Natural products 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 208000031975 Yang Deficiency Diseases 0.000 description 2
- -1 absorption promoters Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 239000008141 laxative Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 230000001543 purgative effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 208000016583 Anus disease Diseases 0.000 description 1
- 241000218236 Cannabis Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000019872 Drug Eruptions Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 208000027534 Emotional disease Diseases 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 235000017443 Hedysarum boreale Nutrition 0.000 description 1
- 235000007858 Hedysarum occidentale Nutrition 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010061245 Internal injury Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 241000405414 Rehmannia Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000037114 Symptom Flare Up Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 229940124532 absorption promoter Drugs 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 1
- 150000004056 anthraquinones Chemical class 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000008142 bulk forming laxative Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 239000009330 huangqi decoction Substances 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 229940007305 lactulose oral solution Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000697 sensory organ Anatomy 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/808—Scrophularia (figwort)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/346—Platycodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
- A61K36/575—Magnolia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
- A61K36/8888—Pinellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8968—Ophiopogon (Lilyturf)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9064—Amomum, e.g. round cardamom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a traditional Chinese medicine composition for treating constipation and application thereof, and relates to the technical field of traditional Chinese medicines. The traditional Chinese medicine composition comprises, by weight, 30 parts of radix scrophulariae, 24 parts of radix ophiopogonis, 24 parts of radix rehmanniae recen, 30 parts of fructus aurantii, 15 parts of mangnolia officinalis, 8 parts of fructus amomi, 10 parts of liquorice, 10 parts of ginger processed pinellia and 10 parts of platycodon grandiflorum. The traditional Chinese medicine composition is refined, reasonable in compatibility, has the effects of increasing liquid, moving the boat, and relaxing the bowels, and has a good curative effect and few side effects on constipation with syndrome differentiation of yin deficiency in traditional Chinese medicine. Clinical tests show that the traditional Chinese medicine composition is obviously superior to a control group in treating constipation caused by yin deficiency. The total effective rate of the treatment group reaches 94.12 percent, and the recurrence rate is low.
Description
Technical Field
The invention relates to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for treating constipation and application thereof.
Background
Functional constipation is a common disease of the digestive system, and is a group of pathological changes without obvious organic properties, which are mainly characterized by the reduction of defecation frequency, the reduction of excrement quantity, excrement drying and hard defecation. Epidemiological data show that the incidence rate of constipation in China is 3% -17%. With the accelerated development of our society, the living rhythm of people is increasingly accelerated, the emotional tension degree is increased by the competitive pressure, and the incidence rate of functional constipation is increased year by year under the influence of various comprehensive factors such as more and more refined dietary structure and the like, so that the living quality of people is seriously influenced. In addition, constipation can not only cause anal diseases such as hemorrhoids, fissures and the like, but also induce and aggravate various cardiovascular and cerebrovascular diseases, and seriously even endanger life.
Factors causing functional constipation are currently considered to include abnormal motility of the intestinal tract, abnormal secretion function of the intestinal tract, abnormal microecological environment of the intestinal tract, etc., but the specific mechanism is not yet clear. At present, functional constipation is treated by western medicine, such as diet, physical exercise and the like, and also by medicines, enema, biofeedback and the like, wherein the medicine treatment has a great proportion. The common medicines comprise various purgatives, prokinetic medicines, secretion-promoting medicines, microecological preparations and the like, but the various medicines have different curative effects and certain side effects, for example, irritant purgatives contain anthraquinone substances, are easy to cause tolerance and dependence after long-term use and can cause the melanosis of the colon. The decomposition of cellulose in bulk laxatives in the intestine leads to gas production and may cause adverse effects such as abdominal distension. At present, no medicine with obvious curative effect is available for treating constipation, especially chronic and intractable constipation.
Constipation has been known for a long time in TCM, and the earliest record is recorded in Huangdi's classic on constipation. The traditional Chinese medicine considers that the food is drunk by people in the stomach and transported and transformed by the spleen and stomach, food essence is used by the body, and the residual dregs are conducted by the large intestine and discharged out of the body through the soul gate, wherein the dregs are excrement. For example, when the spleen and stomach function of transportation and transformation are normal and the large intestine conducts normally, the stool is natural and smooth, wherein the function of large intestine conduction is the key to normal defecation, as stated in Huangdi's classic questions: so that the large intestine and the conductive sense organ become transformed, this is so. Improper diet, emotional disorder or weakness and fatigue cause dysfunction of viscera, which may cause dysfunction of spleen and stomach in transportation and transformation, dysfunction of large intestine in conduction, dregs in intestinal tract, accumulation for a long time, hard and dry feces, difficult to emerge and constipation. The traditional Chinese medicine considers that the human body is an organic whole, and analyzes the changes of the internal organs, the channels and collaterals, the joints, the qi, the blood and the body fluids of the human body by hearing and hearing the four diagnostic and combined references, thereby carrying out treatment based on syndrome differentiation, restoring and harmonizing yin and yang of the human body and self-healing the diseases. The disease location of constipation is in the large intestine, but it is closely related to the dysfunction of the spleen, stomach, liver, kidney and other viscera, and the pathological nature of the constipation includes four aspects of deficiency, excess, cold and heat. Therefore, in treatment, deficiency and excess are distinguished first, and then cold and heat are distinguished. The excess constipation can be classified into heat constipation and qi constipation, and the heat constipation can clear heat and moisten intestines, and the recipe is modified by fructus Cannabis pill; modified Liumo Tang is used for the recipe for qi stagnation. Deficiency syndrome can be classified into qi deficiency, blood deficiency, yin deficiency and yang deficiency type, and qi-tonifying and intestine-moistening for constipation due to qi deficiency, and the formula is modified with Huangqi decoction; for constipation due to blood deficiency, blood-nourishing and dryness-moistening, modified Changchun Wan is used in the recipe; for constipation due to yin deficiency, add or subtract Zengye Tang in the recipe; for constipation due to yang deficiency, it is added or subtracted with Jichuan decoction. However, the clinical results show that the recipe is rarely used.
Various Chinese patent applications (CN114306465A, CN110448629A and CN113181277A) disclose Chinese medicinal compositions for treating constipation, but the Chinese medicinal compositions for treating constipation and the application thereof are not reported at present.
Disclosure of Invention
The invention aims to provide a traditional Chinese medicine composition for treating constipation and application thereof, aiming at the defects of the prior art.
In order to achieve the purpose, the invention adopts the technical scheme that:
in a first aspect, the invention provides a traditional Chinese medicine composition for treating yin deficiency type constipation, which is prepared from 20-30 parts by weight of radix scrophulariae, 20-24 parts by weight of radix ophiopogonis, 20-24 parts by weight of radix rehmanniae recen, 20-30 parts by weight of fructus aurantii, 10-15 parts by weight of cortex magnoliae officinalis, 5-8 parts by weight of fructus amomi and 8-10 parts by weight of liquorice.
Preferably, the traditional Chinese medicine composition is prepared from 30 parts by weight of radix scrophulariae, 24 parts by weight of radix ophiopogonis, 24 parts by weight of radix rehmanniae recen, 30 parts by weight of fructus aurantii, 15 parts by weight of cortex magnoliae officinalis, 8 parts by weight of fructus amomi and 10 parts by weight of liquorice.
Further preferably, the traditional Chinese medicine composition further comprises one or more of ginger processed pinellia tuber and platycodon root. More preferably, the Chinese medicinal composition further comprises ginger processed pinellia tuber and platycodon root.
Most preferably, the traditional Chinese medicine composition is prepared from 30 parts by weight of radix scrophulariae, 24 parts by weight of radix ophiopogonis, 24 parts by weight of radix rehmanniae recen, 30 parts by weight of fructus aurantii, 15 parts by weight of mangnolia officinalis, 8 parts by weight of fructus amomi, 10 parts by weight of liquorice, 10 parts by weight of ginger processed pinellia and 10 parts by weight of platycodon grandiflorum.
Further, the traditional Chinese medicine composition also comprises a pharmaceutically acceptable carrier.
Furthermore, the dosage form of the traditional Chinese medicine composition is decoction, mixture, granules, tablets, capsules or pills.
In a second aspect, the present invention provides a preparation method of the above-mentioned traditional Chinese medicine composition, comprising the step of weighing the raw materials according to the weight part ratio.
In a third aspect, the invention provides an application of the traditional Chinese medicine composition in preparing a medicine for treating constipation.
Further, the invention provides application of the traditional Chinese medicine composition in preparing a medicine for treating yin deficiency type constipation.
Square solution:
functional constipation is mainly caused by abnormal conduction in the large intestine, and although the disease location is in the large intestine, it is also related to dysfunction of various viscera. The Qing Dynasty famous medicine Wu Huang considers that constipation after warm disease is not limited to hot junction and dry liquid. Excess syndrome of heat accumulation caused by excessive yang evil is treated according to the concept of Chengqi decoction; for the half deficiency and half excess syndrome due to yin deficiency and fluid dryness, qi-supporting decoction should not be used, and the fluid-increasing and boat-moving should be used. Therefore, the prescription is mainly 'soup for increasing fluid', and the monarch drug figwort is mainly used for one or two in the prescription, so that the medicine can strengthen water to relieve internal heat and promote diuresis, so that the medicine is mainly used for treating cold heat accumulation in abdomen, and has the effects of clearing heat and relieving dryness, namely the effects of nourishing yin and moistening dryness; radix Ophiopogonis is sweet and cold in nature and moist, radix rehmanniae is used for clearing heat and moistening dryness and nourishing yin and strengthening water to strengthen the effects of nourishing yin and moistening dryness, and the three herbs are used for tonifying yin and fluid and increasing body fluid, so that water is full of the boat and floats; fructus aurantii and cortex magnoliae officinalis are added as ministers to promote qi circulation and dredge river channels and assist the boat to move forwards on the basis of increasing liquid; a little amomum fruit and ginger processed pinellia are further added to prevent the stomach from being injured by large-dose yin-nourishing cold-cold products; the platycodon root is added to ventilate lung qi, and the liquorice is taken to regulate the effects of the traditional Chinese medicines and remove the cold and heat of the five internal organs and six internal organs when the lung is in exterior and interior with the large intestine being taken and the pot is taken to be uncovered. The prescription can be used for treating various dry stools caused by internal injury of yin and fluid deficiency, such as yangming warm disease, large damage of yin fluid and constipation.
Term(s) for
As used herein, an ingredient of the term "pharmaceutically acceptable" is one that is suitable for use in humans and/or animals without undue adverse side effects (such as toxicity, irritation, and allergic response), i.e., at a reasonable benefit/risk ratio.
As used herein, the term "pharmaceutically acceptable carrier" refers to a carrier for administration of a therapeutic agent, including various excipients and diluents and the like. The term refers to such pharmaceutical carriers: they are not essential active ingredients per se and are not unduly toxic after administration. Suitable carriers are well known to those of ordinary skill in the art. In addition, auxiliary substances such as emulsifiers, fillers, binders, wetting agents, absorption promoters, colorants, cosolvents, excipients, flavors, and the like may also be present in these carriers.
As used herein, "parts by weight" can be any fixed weight expressed in milligrams, grams, or kilograms (e.g., 1mg, 1g, 2g, 5g, or 1kg, etc.). In the composition, the percentage content of a certain component is (parts by weight of the component/sum of parts by weight of all components) × 100%. The daily dosage for adults can be determined according to pharmacopoeia.
Dosage forms
The dosage form of the traditional Chinese medicine composition is not particularly limited, and can be any dosage form suitable for being taken by mammals; preferably, the dosage form may be selected from: decoction, mixture, granule, tablet, capsule or pill. From the standpoint of ease of preparation, administration or taking, the preferred Chinese medicinal composition is a solid composition, especially a granule. Oral administration is preferred.
The composition of the present invention may be added with various conventional carriers or adjuvants, such as fillers (e.g. starch), antioxidants or coating materials, etc., which are required in the preparation of different dosage forms. Can be prepared into any common dosage form such as decoction, mixture, granule, tablet, capsule or pill by conventional Chinese medicinal preparation method.
Preparation method
After knowing the raw materials and their formulation used in the Chinese medicinal composition of the present invention, those skilled in the art can process the raw materials into drugs by various conventional methods. Such processing includes, but is not limited to: pulverizing, extracting with water, extracting with organic solvent, etc. More specifically, the processing steps include: weighing, pulverizing, decocting, etc.
The raw materials can be mixed and then the effective components are extracted by a proper method to prepare the traditional Chinese medicine composition; in addition, the effective components can also be extracted respectively (for example, the same or different extraction or processing methods are adopted respectively) and then combined to prepare the traditional Chinese medicine composition.
In addition, the technicians in the field can also directly adopt the effective parts of the raw material medicines for processing so as to prepare the traditional Chinese medicine composition. Furthermore, those skilled in the art can extract active ingredients from the raw materials, mix and process the active ingredients to prepare the traditional Chinese medicine composition.
Optionally, other pharmaceutically (or dietetically or nutraceutically) acceptable carriers can be added during the preparation process. The traditional Chinese medicine can be prepared into other external preparations according to different conditions and pharmaceutical factory conditions.
Use and method of use
The traditional Chinese medicine composition can be directly used for treating constipation, and has a good effect on syndrome differentiation of traditional Chinese medicine, wherein the syndrome is mainly yin deficiency.
The amount of the Chinese medicinal composition of the present invention to be used may vary depending on the mode of administration, the dosage form and the severity of the disease to be treated. For example, individual doses may be administered several times per day in divided doses, or the doses may be reduced proportionally as required by the condition being treated. Of course, the particular dosage will also take into account such factors as the mode of administration, the physical condition of the subject being administered, and the like, which are within the skill of the art.
Detailed Description
The present invention is further illustrated below with reference to specific embodiments, which are given for the purpose of illustration only and are not intended to limit the scope of the present invention. The examples provided below serve as a guide for further modifications by a person skilled in the art and do not constitute a limitation of the invention in any way.
Example 1
20 parts of figwort, 20 parts of dwarf lilyturf tuber, 20 parts of radix rehmanniae recen, 20 parts of bitter orange, 10 parts of officinal magnolia bark, 5 parts of villous amomum fruit and 8 parts of liquoric root to obtain the traditional Chinese medicine composition No. 1.
Example 2
30 parts of figwort, 24 parts of dwarf lilyturf tuber, 24 parts of radix rehmanniae recen, 30 parts of bitter orange, 15 parts of officinal magnolia bark, 8 parts of villous amomum fruit and 10 parts of liquoric root to obtain the traditional Chinese medicine composition No. 2.
Example 3
30 parts of radix scrophulariae, 24 parts of radix ophiopogonis, 24 parts of radix rehmanniae recen, 30 parts of fructus aurantii, 15 parts of mangnolia officinalis, 8 parts of fructus amomi, 10 parts of liquorice, 10 parts of ginger processed pinellia ternate and 10 parts of platycodon grandiflorum to obtain the traditional Chinese medicine composition No. 3.
Example 4
The raw materials are respectively taken according to the weight parts of the components in the embodiments 1-3, cleaned and placed in a stainless steel pot, added with water, the water is added to the pot to be higher than the components by 3cm, soaked for 30min, boiled by big fire, decocted by small fire for 20min, and the juice is about 150 ml. Adding water again to 2cm above the materials, boiling with strong fire, decocting with slow fire for 30min to obtain about 150ml decoction, and mixing decoctions to obtain decoction.
Example 5
The raw materials are respectively taken according to the weight parts of the raw materials in the embodiments 1 to 3, then the raw materials are prepared into decoction according to the embodiment 4, insoluble substances are filtered by adopting an ethanol precipitation purification method, ethanol is recovered, and the decoction is heated and concentrated by adopting steam until the daily dose of the decoction is 20 to 30 milliliters for adults. Sterilizing, adding antiseptic, packaging, and making into mixture.
Example 6
The raw materials are respectively taken according to the weight part ratio of the embodiments 1 to 3, then the decoction is prepared according to the embodiment 4, the decoction is concentrated until the relative density is 1.20g/ml, the decoction is cooled, 2 times of ethanol is added, the mixture is stirred and stood, the supernatant fluid is filtered, the filtrate is steamed to have no alcohol smell, the standing is carried out, the supernatant fluid is taken and decompressed and concentrated to obtain the extract, and the extract is dried and crushed into particles, thus preparing the granules.
Example 7
The raw materials are taken according to the weight part ratio of the embodiments 1 to 3 respectively, then the decoction is prepared according to the embodiment 4, the decoction is concentrated until the relative density is 1.20g/ml, the decoction is cooled, 2 times of ethanol is added, the mixture is stirred and stood, the supernatant fluid is filtered, the filtrate is steamed to have no alcohol smell, the standing is carried out, the supernatant fluid is taken and decompressed and concentrated to obtain extract, the pharmaceutical auxiliary materials are added, the vacuum drying is carried out, the crushing and the granulation are carried out, the tablet or the filling and the capsule are pressed to prepare the tablet or the capsule.
Example 8
The raw material medicines are respectively taken according to the weight parts of the raw materials in the embodiments 1-3, crushed into fine powder, sieved by a 80-mesh sieve for later use, a certain amount of honey is weighed, the honey is heated in an evaporation dish until boiling (if impurities can be filtered), the honey is continuously refined to the refined honey degree, and floating foams are fished out; mixing refined honey and the medicinal powder at a ratio of 1:1, and mixing thoroughly; manually or with mold, making into smooth and spherical pill, wrapping with wax paper, and making into pill.
Example 9
Clinical trial
1 clinical data
Collecting functional constipation patients treated in the hospital, selecting 102 cases of yin deficiency syndrome in traditional Chinese medicine differentiation, and randomly dividing into a control group and a traditional Chinese medicine according to a random number table method. The difference between the two groups in terms of gender, age, and disease course has no statistical significance and is comparable.
2 method of treatment
The control group was orally administered lactulose oral solution (size: 100 mL/bottle, lot No. 17193721, Fresenius Kabi Austria GmbH) at an initial dose of 30mL 2 times daily, and 1 week later a maintenance dose of 20mL 2 times daily was administered. The treatment course is 4 weeks.
The traditional Chinese medicine group oral traditional Chinese medicine composition No. 3: 30g of figwort root, 24g of dwarf lilyturf tuber, 24g of raw rehmannia root, 30g of bitter orange, 15g of officinal magnolia bark and villous amomum fruit (rear lower) 8g and licorice root 10 g. 10g of ginger processed pinellia tuber and 10g of balloonflower root, 1 dose of which is decocted in water for 400mL each day, and the decoction is taken warm for 30min after meal for 2 times. The treatment course is 4 weeks.
3 observation index
3.1 clinical efficacy
A constipation symptom scoring table is formulated by referring to 'consensus opinion of traditional Chinese medicine diagnosis and treatment experts on constipation' (2017), Bristol excrement typing standard and 'assessment of constipation symptom and curative effect', and is detailed in Table 1.
TABLE 1 Constipation symptom Scale Table
3.2 laboratory test index
Before and after treatment, 5mL of venous blood is respectively taken, and serum Motilin (MTL) and Gastrin (GAS) levels of two groups of patients before and after treatment are detected and recorded by adopting a Hitachi 7600 type full-automatic biochemical analyzer; the ELISA method measures serum Substance P (SP), Nitric Oxide (NO) levels before and after treatment in both groups.
3.3 adverse reactions
The liver function results before and after treatment and the adverse reactions such as abdominal pain, diarrhea, dizziness, nausea, drug eruption during treatment were recorded for two groups of patients.
3.4 therapeutic criteria
Refer to "consensus opinion of Constipation TCM diagnosis and treatment experts (2017)". And (3) healing: the symptom improvement rate is more than or equal to 80 percent; the effect is shown: the symptom improvement rate is more than or equal to 50 percent and less than 80 percent; the method has the following advantages: the symptom improvement rate is more than or equal to 30 percent and less than 50 percent; and (4) invalidation: the symptom improvement rate is less than 30%. Total effective rate (%) - (number of cure cases + number of significant cases + number of effective cases)/total number of cases × 100%. The recurrence is determined when the symptom increase rate is more than or equal to 50%. Relapse rate (%) — number of relapses/total number of effective cases × 100%.
3.5 statistical methods
Each data was analyzed using SPSS20.0 to (x) 2 S) representing each measurement data, and using t to test; each count data is represented by a ratio (%) and x 2 And (5) checking, and checking the grade data by using a rank sum. The difference is statistically significant when P is less than 0.05.
4 results
4.1 clinical efficacy
Two groups of clinical curative effects and 3 months relapse rate: the total effective rate of the control group is 80.39%, the total effective rate of the traditional Chinese medicine is 94.12%, and the traditional Chinese medicine group is obviously higher than the control group (P is less than 0.01). After 3 months of treatment, the relapse rate of the control group is 36.59 percent, the relapse rate of the traditional Chinese medicine group is 10.42 percent, and the traditional Chinese medicine group is obviously lower than the control group (P is less than 0.01). See table 2.
TABLE 2 comparison of clinical efficacy and 3-month relapse Rate [ case (%) ]
Note: compared with the control group, the compound of the formula, ** P<0.01。
4.2 serum MTL, GAS profiles before and after treatment in both groups
Compared with the levels of MTL and GAS in serum before two groups of treatment, the difference has no statistical significance; the MTL and GAS levels of the two groups after treatment are obviously higher than those before treatment (P is less than 0.01), and the MTL and GAS levels of the traditional Chinese medicine groups after treatment are obviously higher than those of the control group (P is less than 0.01). See table 3.
TABLE 3 serum MTL, GAS profiles before and after treatment in two groups (x) 2 ±s,ng/L)
Note: compared with the group before treatment, ** P<0.01; compared with the control group at the same time, △△ P<0.01. the same applies to Table 4.
4.3 serum SP, NO status before and after two groups of treatments
The differences of two groups of serum SP and NO before treatment have NO statistical significance; after treatment, SP levels are obviously increased (P is less than 0.01) compared with before treatment, NO levels are obviously reduced (P is less than 0.01) compared with before treatment, after treatment, SP levels of the traditional Chinese medicine group are obviously higher than that of a control group (P is less than 0.01), and NO levels are obviously lower than that of the control group (P is less than 0.01). See table 4.
TABLE 4 serum SP, NO status before and after two groups of treatment (x) 2 ±s)
3.4 adverse reaction of two groups of patients
The liver function is basically normal before the two groups of medicines are taken, and no obvious abnormality exists after the liver function is rechecked after treatment; the incidence rate of adverse reactions of the control group is 15.69%, the incidence rate of adverse reactions of the traditional Chinese medicine group is 3.92%, and the traditional Chinese medicine group is obviously lower than the control group (P is less than 0.05). See table 5.
TABLE 5 adverse reactions in two groups of patients
Note: compared with the control group, the compound of the formula, * P<0.05。
the foregoing is only a preferred embodiment of the present invention, and it should be noted that, for those skilled in the art, various modifications and additions can be made without departing from the principle of the present invention, and these should also be considered as the protection scope of the present invention.
Claims (10)
1. A traditional Chinese medicine composition for treating constipation is characterized by being prepared from 20-30 parts by weight of radix scrophulariae, 20-24 parts by weight of radix ophiopogonis, 20-24 parts by weight of radix rehmanniae recen, 20-30 parts by weight of fructus aurantii, 10-15 parts by weight of mangnolia officinalis, 5-8 parts by weight of fructus amomi and 8-10 parts by weight of liquorice, and is mainly used for treating constipation with syndrome differentiation of yin deficiency in traditional Chinese medicine.
2. The traditional Chinese medicine composition of claim 1, wherein the traditional Chinese medicine composition is prepared from 30 parts by weight of radix scrophulariae, 24 parts by weight of radix ophiopogonis, 24 parts by weight of radix rehmanniae recen, 30 parts by weight of fructus aurantii, 15 parts by weight of cortex magnoliae officinalis, 8 parts by weight of fructus amomi and 10 parts by weight of liquorice.
3. The Chinese medicinal composition of claims 1-2, wherein the Chinese medicinal composition further comprises one or more of pinellia ternata and platycodon grandiflorum.
4. The Chinese medicinal composition of claim 3, wherein the Chinese medicinal composition further comprises ginger processed pinellia tuber and platycodon grandiflorum.
5. The Chinese medicinal composition according to claim 4, wherein the Chinese medicinal composition is prepared from 30 parts by weight of radix scrophulariae, 24 parts by weight of radix ophiopogonis, 24 parts by weight of radix rehmanniae recen, 30 parts by weight of fructus aurantii, 15 parts by weight of cortex magnoliae officinalis, 8 parts by weight of fructus amomi, 10 parts by weight of liquorice, 10 parts by weight of ginger processed pinellia and 10 parts by weight of platycodon grandiflorum.
6. The Chinese medicinal composition of any one of claims 1-5, wherein the Chinese medicinal composition further comprises a pharmaceutically acceptable carrier.
7. The traditional Chinese medicine composition according to any one of claims 1 to 5, wherein the dosage form of the traditional Chinese medicine composition is decoction, mixture, granule, tablet, capsule or pill.
8. The preparation method of the traditional Chinese medicine composition as claimed in any one of claims 1 to 7, which is characterized by comprising the step of weighing the raw materials according to the weight part ratio.
9. Use of the Chinese medicinal composition of any one of claims 1-7 in the preparation of a medicament for treating constipation.
10. Use of the Chinese medicinal composition of any one of claims 1-7 in the preparation of a medicament for treating yin deficiency type constipation.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210729676.9A CN114869982A (en) | 2022-06-25 | 2022-06-25 | Traditional Chinese medicine composition for treating constipation and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210729676.9A CN114869982A (en) | 2022-06-25 | 2022-06-25 | Traditional Chinese medicine composition for treating constipation and application thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114869982A true CN114869982A (en) | 2022-08-09 |
Family
ID=82682235
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210729676.9A Pending CN114869982A (en) | 2022-06-25 | 2022-06-25 | Traditional Chinese medicine composition for treating constipation and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114869982A (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102188606A (en) * | 2010-12-08 | 2011-09-21 | 叶建斌 | Formula and preparation method of Yangyin Runfei Effervescent Tablets |
-
2022
- 2022-06-25 CN CN202210729676.9A patent/CN114869982A/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102188606A (en) * | 2010-12-08 | 2011-09-21 | 叶建斌 | Formula and preparation method of Yangyin Runfei Effervescent Tablets |
Non-Patent Citations (2)
Title |
---|
孙兴伟, 等: "增液汤加味治疗功能性便秘阴液亏虚证的临床疗效观察", 《中华中医药杂志》, vol. 37, no. 03, pages 1819 * |
王耀: "中医辨证治疗老年性便秘68例", vol. 15, no. 03, pages 204 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3947012B2 (en) | Diabetes treatment composition | |
CN105727145A (en) | Traditional Chinese medicine drug for treating spleen deficiency phlegm-dampness syndrome type hyperlipidaemia | |
CN106362020B (en) | A kind of pine pollen composition and preparation method thereof with improvement defecating feces excretion | |
CN111729054A (en) | Dampness-resolving toxin-vanquishing traditional Chinese medicine composition, traditional Chinese medicine preparation, preparation method and application thereof | |
CN104873705A (en) | Medicinal composition for treating angina pectoris of coronary heart disease and application thereof | |
CN102772491A (en) | Traditional Chinese medicine composition for treating lower extremity atherosclerotic disease and application of composition | |
CN111298021A (en) | Traditional Chinese medicine composition for treating functional constipation | |
CN110064016A (en) | A kind of Chinese medicine composition and preparation method thereof adjusting chronic kidney disease immune state | |
JP7340113B2 (en) | Chinese herbal composition and its production method and use | |
CN102430008B (en) | Chinese medicinal composition for treating gastrointestinal disease and preparation method thereof | |
CN114869982A (en) | Traditional Chinese medicine composition for treating constipation and application thereof | |
CN104225016B (en) | A kind of pharmaceutical composition treating due to weakness of spleen and stomach chronic atrophic gastritis | |
CN107007702A (en) | A kind of Chinese medicine composition and its preparation for treating osteoarthropathy | |
CN112675271A (en) | Traditional Chinese medicine composition for treating internal abnormality and application thereof | |
CN116350686B (en) | Medicinal and edible traditional Chinese medicine composition for treating dental ulcer and preparation method thereof | |
CN116942771B (en) | Traditional Chinese medicine composition for treating coronary heart disease and application thereof | |
CN109010621A (en) | A kind of Chinese medicine composition that treating diabetes, preparation method and applications | |
CN114796389B (en) | Composition for treating chronic pharyngitis | |
CN115998820B (en) | Pharmaceutical composition for treating constipation and preparation method and use thereof | |
CN117045764B (en) | Traditional Chinese medicine composition for treating type II diabetes and preparation method thereof | |
CN114432411B (en) | A traditional Chinese medicine composition for treating chronic kidney disease proteinuria, its preparation method and application | |
CN112089783B (en) | Application of traditional Chinese medicine composition in the preparation of medicine for preventing or/and treating obesity | |
CN101167915B (en) | Traditional Chinese medicine for treating chronic superficial gastritis and its preparation method | |
CN101380451B (en) | Preparation method of no-alcohol type Liusheng Qushu liquid oral preparation | |
CN107929354A (en) | A kind of pharmaceutical composition for treating calculus and its preparation method and application |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220809 |
|
RJ01 | Rejection of invention patent application after publication |